Mereo Biopharma Group PLC
NASDAQ:MREO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.3
4.87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Mereo Biopharma Group PLC
Wall Street
Price Targets
MREO Price Targets Summary
Mereo Biopharma Group PLC
According to Wall Street analysts, the average 1-year price target for
MREO
is 7.1 USD
with a low forecast of 5.76 USD and a high forecast of 8.4 USD.
MREO Last Price Targets
Mereo Biopharma Group PLC
The latest public price target was made on Jun 20, 2024 by
Joseph Schwartz
from
Leerink Partners
,
who expects
MREO
stock to
rise by 139%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Joseph Schwartz
Leerink Partners
|
8
USD
Upside 139% |
6 months ago
Jun 20, 2024
|
Mereo BioPharma price target raised to $8 from $6 at Leerink
TheFly
|
Gil Blum
Needham
|
7
USD
Upside 109% |
6 months ago
Jun 12, 2024
|
Mereo BipPharma Group (MREO) PT Raised to $7 at Needham
StreetInsider
|
Jack Allen
Robert W. Baird
|
8
USD
Upside 139% |
6 months ago
Jun 12, 2024
|
Baird Starts Mereo BipPharma Group (MREO) at Outperform
StreetInsider
|
|
Gil Blum
Needham
|
6
USD
Upside 79% |
8 months ago
Mar 28, 2024
|
Mereo BipPharma Group (MREO) PT Raised to $6 at Needham on increased 'launch expectations for setrusumab in OI'
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is MREO's stock price target?
Price Target
7.1
USD
According to Wall Street analysts, the average 1-year price target for
MREO
is 7.1 USD
with a low forecast of 5.76 USD and a high forecast of 8.4 USD.
What is Mereo Biopharma Group PLC's Revenue forecast?
Projected CAGR
67%
The
compound annual growth rate
of Mereo Biopharma Group PLC's revenue for the next 4 years is
67%.
You don't have any saved screeners yet
